Press Release Details

Agios to Present IDH Program Insights at AACR-NCI-EORTC International Conference

Oct 18, 2013
PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 18, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that the company will present insights into its lead isocitrate dehydrogenase (IDH) program at the at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 19-23, 2013 in Boston.

The schedule for Agios’ presentation is as follows:

Date & Time:

  Sunday, October 20, 2013, 3:15-5:15 p.m. GMT

Session:

Plenary Session 2: Targeting the Metabolic Basis of Cancer

Title:

Targeting IDH mutations in cancer

Presenter:

Katharine Yen, Ph.D., director, biology

For more information about the conference, see the full program here.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare metabolic genetic diseases (known as inborn errors of metabolism or IEMs) through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and preclinical development. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “believe,” “expect” “could,” “should,” “will,” “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to important risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs, including the risks described under the caption “Risk Factors” in Agios’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 which is on file with the Securities and Exchange Commission (SEC), and other filings that Agios may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Agios Pharmaceuticals, Inc.

For Agios Pharmaceuticals, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com